<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216311434953</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216311434953</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A case of possible glossitis in a patient with non small cell carcinoma of the lung secondary to levomepromazine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Murray-Brown</surname><given-names>Fay Louise</given-names></name>
</contrib>
<aff id="aff1-0269216311434953">Christchurch Hospital, UK</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216311434953">Fay Louise Murray-Brown, Macmillan Unit, Christchurch Hospital, Fairmile Road, Christchurch BH23 2JX, UK. Email: <email>faythemedic@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>6</issue>
<fpage>860</fpage>
<lpage>861</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Levomepromazine at a low dose is regularly used in palliative care with good success to control nausea and vomiting in the UK.<sup><xref ref-type="bibr" rid="bibr1-0269216311434953">1</xref></sup> The following case report describes an unusual side effect of this agent.</p>
<sec id="section1-0269216311434953">
<title>Case history</title>
<p>A 73-year-old lady was diagnosed with non small cell carcinoma of the lung with bony metastases. She received a single fraction of radiotherapy to a rib deposit and was awaiting chemotherapy when she was admitted with vomiting unresponsive to domperidone. Her other medication included morphine sulphate, naproxen, paracetamol, ezetimibe, bisoprolol, isosorbide mononitrate, ferrous sulphate and co-danthramer. She was commenced on 6.25mg levomepromazine orally at night with good effect, but 5 days later complained of a sore mouth. Examination revealed angular stomatitis and bloods showed a normocytic anaemia, with normal folate and B12. Thrush treatment with nystatin and canesten, and oral gels for dry mouth were commenced and she was discharged home on the same dose of levomepromazine.</p>
<p>Seven days later she was readmitted with worsening nausea and vomiting and levomepromazine was increased to 12.5mg BD but after another 7 days she complained of a worsening sore mouth. Examination revealed a red, shiny, beefy tongue indicative of glossitis. Herpes simplex swab was negative. Mouthwashes were commenced with no effect and all drugs were reviewed. Co-danthramer, naproxen, ezetimibe and ferrous sulphate were discontinued with no improvement within 4 days. Levomepromazine was then discontinued and changed to haloperidol and within 3 days her mouth was vastly improved and she was able to eat and drink again, allowing discharge later that week.</p>
</sec>
<sec id="section2-0269216311434953">
<title>Discussion</title>
<p>Glossitis is described as redness and soreness of the tongue. The dorsum of the tongue anterior to the V-shaped line formed by the circumvallate papillae is covered by mucosa consisting of numerous filiform papillae.<sup><xref ref-type="bibr" rid="bibr2-0269216311434953">2</xref></sup> Glossitis is a painful inflammatory condition associated with partial or complete loss of filiform papillae,<sup><xref ref-type="bibr" rid="bibr3-0269216311434953">3</xref></sup> with shedding of the epithelium and, eventually, ulceration. Glossitis can be caused by bacterial or viral infections, colonisation by oral thrush, iron-deficiency anaemia, folate and B vitamin deficiencies, exposure to irritants such as tobacco and alcohol, allergic reactions to mouthwash or toothpaste, and drug-induced causes.</p>
<p>Postulated mechanisms of action for drug-induced oral mucous membrane lesions include disintegration of epithelial cell structures by a direct action on the cell membrane, inhibition of intracellular enzymes essential for cell maintenance and injury to cells by harmful drug metabolites.<sup><xref ref-type="bibr" rid="bibr4-0269216311434953">4</xref></sup> The temporal relationship with sore mouth following levomepromazine commencement, severe glossitis following its increased dose and its resolution with its discontinuation suggest that this patient’s glossitis was caused by this agent. The mechanism by which levomepromazine induces acute glossitis is unknown, although it may be hypothesised, based upon the delayed development of adverse effects until approximately 1 week after initiation of high dose therapy, that a drug-induced inhibition of intracellular enzymes is responsible for the glossitis.</p>
<p>Although there is no published literature directly pertaining to glossitis secondary to levomepromazine, it, being a 5HT-2 receptor antagonist<sup><xref ref-type="bibr" rid="bibr5-0269216311434953">5</xref></sup> and alpha-1-adrenergic blocking agent,<sup><xref ref-type="bibr" rid="bibr6-0269216311434953">6</xref></sup> has similar pharmacological activity with the tetracyclic antidepressants mianserin and doxepin, for which published associations with glossitis exist.<sup><xref ref-type="bibr" rid="bibr7-0269216311434953">7</xref><xref ref-type="bibr" rid="bibr8-0269216311434953"/>–<xref ref-type="bibr" rid="bibr9-0269216311434953">9</xref></sup></p>
<p>When unexpected oral inflammation and pain occur, the potential for drug-induced oral lesions should be considered, as simply discontinuing an offending drug can prevent escalating doses of potential toxic drugs or the commencement of additional drugs to manage these symptoms. Levomepromazine is increasingly used in the palliative care setting because of its broad actions on the mechanisms leading to nausea. Therefore, it is important to be aware of its side-effect profile.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216311434953">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Twycross</surname><given-names>R</given-names></name>
<name><surname>Barkby</surname><given-names>G</given-names></name>
<name><surname>Hallywood</surname><given-names>P</given-names></name>
</person-group>. <article-title>The use of low dose levomepromazine (methotrimeprazine) in the management of nausea and vomiting</article-title>. <source>Progr Palliat Care</source> <year>1997</year>; <volume>5</volume>: <fpage>49</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr2-0269216311434953">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dreizen</surname><given-names>S</given-names></name>
</person-group>. <article-title>Oral indications of the deficiency states</article-title>. <source>Postgrad Med</source> <year>1971</year>; <volume>54</volume>: <fpage>97</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr3-0269216311434953">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Diagnosis and treatment of commonly occurring mucosal lesions</article-title>. In: <person-group person-group-type="editor">
<name><surname>Mitchell</surname><given-names>DF</given-names></name>
</person-group> (ed) <source>Dental clinics of North America</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>WB Saunders</publisher-name>, <year>1968</year>, pp. <fpage>111</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr4-0269216311434953">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bartelink</surname><given-names>A</given-names></name>
</person-group>. <article-title>Drug-induced diseases of the gastrointestinal tract</article-title>. In: <person-group person-group-type="editor">
<name><surname>Meyler</surname><given-names>LM</given-names></name>
<name><surname>Peck</surname><given-names>HM</given-names></name>
</person-group> (eds) <source>Drug-induced diseases</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Excerpta Medica</publisher-name>, <year>1972</year>, pp. <fpage>403</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr5-0269216311434953">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eisenchlas</surname><given-names>J</given-names></name>
<name><surname>Garrigue</surname><given-names>N</given-names></name>
<name><surname>Junin</surname><given-names>M</given-names></name>
<name><surname>De Simone</surname><given-names>G</given-names></name>
</person-group>. <article-title>Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study</article-title>. <source>Palliat Med</source> <year>2005</year>; <volume>19</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr6-0269216311434953">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>B</given-names></name>
<name><surname>Pettit</surname><given-names>T</given-names></name>
<name><surname>Faith</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Focus on levomepromazine</article-title>. <source>Curr Med Res Opin</source> <year>2004</year>; <volume>20</volume>(<issue>4</issue>): <fpage>1877</fpage>–<lpage>1881</lpage>.</citation>
</ref>
<ref id="bibr7-0269216311434953">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leibovitch</surname><given-names>G</given-names></name>
<name><surname>Maaravi</surname><given-names>Y</given-names></name>
<name><surname>Shalev</surname><given-names>O</given-names></name>
</person-group>. <article-title>Severe facial oedema and glossitis associated with mianserin</article-title>. <source>Lancet</source> <year>1989</year>; <volume>2</volume>(<issue>8667</issue>): <fpage>871</fpage>–<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr8-0269216311434953">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de la Fuente</surname><given-names>J</given-names></name>
<name><surname>Berlanga</surname><given-names>C</given-names></name>
</person-group>. <article-title>Glossitis associated with mianserin</article-title>. <source>Lancet</source> <year>1988</year>; <volume>1</volume>(<issue>8370</issue>): <fpage>233</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr9-0269216311434953">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ives</surname><given-names>T</given-names></name>
<name><surname>Stewart</surname><given-names>R</given-names></name>
</person-group>. <article-title>Doxepin-induced acute glossitis</article-title>. <source>Amer J Hosp Pharm</source> <year>1980</year>; <volume>37</volume>(<issue>11</issue>): <fpage>1551</fpage>–<lpage>1552</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>